Becton, Dickinson and Company BDX, also popularly known as BD, recently received 510(k) clearance for expanded indications from the FDA for the Rotarex Atherectomy System. It is important to mention ...
The FDA issued a warning regarding the Rotarex Atherectomy System, a device used to break up and remove the thrombus from peripheral arteries. Bard Peripheral Vascular, a subsidiary of Becton, ...
The US Food and Drug Administration is alerting the public of a potentially high-risk device issue related to Rotarex Atherectomy Systems (Bard Peripheral Vascular) used in peripheral artery ...
The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular division. According to the agency, BD has reported 30 serious injuries and ...
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)), a leading global medical technology company, today announced plans to initiate a patient data registry for ...
Becton, Dickinson and Company (BD) is set to initiate a multi-centre registry study, XTRACT, of the Rotarex Atherectomy System, aimed at measuring real-world outcomes for individuals with peripheral ...
BD is putting a fresh spin on an old awareness drive, returning to the 12-year-old “Love Your Limbs” campaign to mark Peripheral Artery Disease (PAD) Awareness Month. The company, which sells PAD ...
Becton, Dickinson and Company BDX, also popularly known as BD, recently received 510(k) clearance for expanded indications from the FDA for the Rotarex Atherectomy System. It is important to mention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results